Wire flash
Baili Tianheng unit to invest $5 mln in Connexus Therapeutics
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 17, 2026, Jin10 Data reported that Baili Tianheng announced its wholly-owned subsidiary, Pangu Capital, plans to subscribe for 3.881 million Series A preferred shares of Connexus Therapeutics for a total cash consideration of USD 5 million. Upon completion of the capital increase, Pangu Capital will hold a 7.91% equity stake in Connexus Therapeutics. The transaction is classified as a related-party transaction and was approved by the Board of Directors and the Special Meeting of Independent Directors on September 16, 2026. The company stated that the investment does not require approval from the shareholders' meeting.
Source report
Jin10 Data — September 17 — Baili Tianheng has announced that its wholly-owned subsidiary, Pangu Capital, plans to subscribe for 3.881 million Series A preferred shares of Connexus Therapeutics in cash, at a total investment of USD 5 million.
Upon completion of the capital increase, Pangu Capital will hold a 7.91% equity stake in Connexus Therapeutics.
The transaction constitutes a related-party transaction. It was approved by the Board of Directors and the Special Meeting of Independent Directors on September 16, 2026, and does not require approval from the shareholders' meeting.
Source
金十数据Neutral / independent
Part of this Story
Baili Tianheng subsidiary invests $5 million in Connexus Therapeutics for 7.91% stake